Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PENUMBRA, INC.

(PEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Insider Sell: Penumbra

10/06/2021 | 09:32am EST


© MT Newswires 2021
All news about PENUMBRA, INC.
11/05New Data Demonstrates Safety and Performance of Continuous Aspiration Thrombectomy with..
BU
11/05Penumbra, Inc. Announces CHEETAH Clinical Study of Indigo? System CAT? RX Catheter
CI
11/03PENUMBRA : Q3 Earnings Snapshot
AQ
11/03PENUMBRA INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS ..
AQ
11/03Penumbra, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Sep..
CI
11/03Penumbra, Inc. Reports Third Quarter 2021 Financial Results - Form 8-K
PU
11/03Penumbra Swings to Adjusted Earnings in Q3, Lifts 2021 Revenue Outlook
MT
11/03Earnings Flash (PEN) PENUMBRA Posts Q3 EPS $0.12, vs. Street Est of $0.17
MT
11/03Earnings Flash (PEN) PENUMBRA Posts Q3 Revenue $190.1M, vs. Street Est of $181.1M
MT
11/03Penumbra, Inc. Reports Third Quarter 2021 Financial Results
PR
More news
Analyst Recommendations on PENUMBRA, INC.
More recommendations
Financials (USD)
Sales 2021 738 M - -
Net income 2021 16,3 M - -
Net Debt 2021 - - -
P/E ratio 2021 575x
Yield 2021 -
Capitalization 9 346 M 9 346 M -
Capi. / Sales 2021 12,7x
Capi. / Sales 2022 10,8x
Nbr of Employees 3 300
Free-Float 95,6%
Chart PENUMBRA, INC.
Duration : Period :
Penumbra, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PENUMBRA, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 250,16 $
Average target price 329,83 $
Spread / Average Target 31,8%
EPS Revisions
Managers and Directors
Adam Elsesser Chairman, President & Chief Executive Officer
Maggie S. Yuen Chief Financial Officer
Pankaj Tiwari Vice President-Information Technology
Michaella Corso Vice President-Clinical Affairs
Corey L. Teigen Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
PENUMBRA, INC.42.95%9 346
MASIMO CORPORATION5.88%15 691
GETINGE AB100.52%11 520
NOVOCURE LIMITED-43.94%10 072
SHOCKWAVE MEDICAL, INC.77.02%6 482
ASAHI INTECC CO., LTD.-29.67%6 345